

Daunorubicin

Essential medicine status

General description

Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

INN

Daunorubicin

ATC codes

[L01DB02](#)

Medicine type

Chemical agent

EML status history

First added in 1999 ([TRS 895](#)) for [Lymphoid leukaemia, not elsewhere classified](#)

Added in 1999 ([TRS 895](#)) for [Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Added in 1999 ([TRS 895](#)) for [Myeloid leukaemia](#)

Wikipedia

[Daunorubicin](#)

DrugBank

[Daunorubicin](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

[Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#)